



Chemotherapy: Colorectal Cancer Drugs
Erbix (cetuximab) J9055, Vectibix
(panitumumab) J9303
Prior Authorization Request
Medicare Part B Form

*Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.*

<input type="checkbox"/>	NEW START - Start Date: _____	<input type="checkbox"/>	Continuation (within 365 days): Date of last treatment _____
<input type="checkbox"/>	Date Requested _____		
	Requestor _____	Clinic name: _____	Phone _____ / Fax _____

MEMBER INFORMATION

*Name: _____ *ID#: _____ *DOB: _____

PRESCRIBER INFORMATION

*Name: _____ MD FNP DO NP PA *Phone: _____

*Address: _____ *Fax: _____

DISPENSING PROVIDER / ADMINISTRATION INFORMATION

*Name: _____ Phone: _____

*Address: _____ Fax: _____

PROCEDURE / PRODUCT INFORMATION

HCPC Code	Name of Drug <input type="checkbox"/> Self-administered	Dose (Wt: _____ kg Ht: _____)	Frequency	End Date if known

Chart notes attached. **Other important information:** _____

Diagnosis: ICD10: _____ **Description:** _____

Provider attests the diagnosis provided is an FDA-Approved indication for this drug

CLINICAL INFORMATION

New Start or Initial Request: (Clinical documentation required for all requests)
 Provider has reviewed the attached “Criteria for Approval” and attests the member meets ALL required PA criteria.
 If not, please provide **clinical rationale** for formulary exception: _____

Continuation Requests: (Clinical documentation required for all requests)
 Provider has reviewed the attached “Criteria for Continuation” and attests the member meets ALL required PA Continuation criteria.
 Patient had an adequate response or significant improvement while on this medication.
 If not, please provide clinical rationale for continuing this medication: _____

ACKNOWLEDGEMENT

Request By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT. PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.**

Prior Authorization Group – Oncology: Colorectal Cancer Drugs PA

Drug Name(s):

ERBITUX
VECTIBIX

Criteria for approval of Prior Authorization Drug:

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Prescribed by, or in consultation with an oncologist or other cancer specialist related to the diagnosis.
3. Drug is being used appropriately per CMS recognized compendia, authoritative medical literature, evidence-based guidelines and/or accepted standards of medical practice.
4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
 - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
 - Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

Cannot be prescribed for experimental or investigational use.

Prescriber Restrictions:

Oncologist or other cancer specialist

Coverage Duration:

New Start: Approval will be for 6 months

Continuation: Approval will be for 12 months

FDA Indications:

Erbix

- Metastatic colorectal cancer, KRAS wild-type, EGFR-expressing, as monotherapy, in patients intolerant to irinotecan-based chemotherapy
- Metastatic colorectal cancer, KRAS wild-type, EGFR-expressing, as monotherapy in patients who failed both irinotecan- and oxaliplatin-based regimens
- Metastatic colorectal cancer, KRAS wild-type, EGFR-expressing, first-line therapy, in combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)
- Metastatic colorectal cancer, KRAS wild-type, EGFR-expressing, in combination with irinotecan, in patients refractory to irinotecan-based chemotherapy
- Squamous cell carcinoma of head and neck, Locally or regionally advanced disease, in combination with radiation therapy
- Squamous cell carcinoma of head and neck, Metastatic or recurrent disease, as monotherapy, in patients who failed prior platinum-based therapy
- Squamous cell carcinoma of head and neck, Metastatic or recurrent disease, first-line therapy, in combination with platinum-based chemotherapy with 5-fluorouracil

Vectibix

- Metastatic colorectal cancer, Wild-type RAS (wild-type in both KRAS and NRAS), first-line therapy, in combination with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX regimen)
- Metastatic colorectal cancer, Wild-type RAS (wild-type in both KRAS and NRAS), progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

Off-Label Uses:

Erbix

- Gastric cancer
- Malignant neoplasm of cardio-esophageal junction of stomach
- Metastatic colorectal cancer, EGFR-expressing, in combination with irinotecan, in patients who failed both fluoropyrimidine- and oxaliplatin-based regimens
- Metastatic colorectal cancer, Refractory, non-epidermal growth factor receptor (EGFR) expressing
- Squamous cell carcinoma of head and neck, Metastatic or recurrent disease, refractory to platinum-based therapy, as combination therapy

Vectibix

- Metastatic colorectal cancer, Wild-type KRAS mutation, second-line therapy following fluoropyrimidine-containing chemotherapy, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen)
- Non-small cell lung cancer, Advanced

Age Restrictions:

Safety and effectiveness not established in pediatric patients

Other Clinical Considerations:

Cancer diagnoses: Criteria as per NCCN or other FDA-approved cancer related guidelines.

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/50B6A9/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/304A33/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=928013&contentSetId=100&title=Cetuximab&servicesTitle=Cetuximab&brandName=Erbix&UserMdxSearchTerm=ERBITUX&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/DF25A9/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/00F87C/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=928625&contentSetId=100&title=Panitumumab&servicesTitle=Panitumumab&brandName=Vectibix&UserMdxSearchTerm=Vectibix&=null#